Skip to main content

Advertisement

SpringerLink
Log in

Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant

  • Clinical study - patient study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

We report a single-center experience of 16 immunocompetent patients diagnosed with primary central nervous system lymphoma and treated with monochemotherapy with high-dose methotrexate (MTX) and deferred radiotherapy. MTX was given at a dose of 8.0 g/m2 for induction and at a dose of 3.5–8.0 g/m2 for maintenance. There were eight complete responses (CR), one partial response, one stable disease, and six patients whose tumors progressed in spite of the chemotherapy. At final follow-up, five of five CRs were alive and well without radiotherapy, with median follow-up of 26 months. Overall survival in eight non-CRs treated with the subsequent radiotherapy was 36 months. In the immunohistochemical study, STAT6 was positively expressed in 8 out of 13 cases. They included all non-CRs and two CRs. This observation suggests that STAT6 expression can be used as a prognostic determinant for MTX chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tseng MY, Tu YK, Shun CT (1998) Primary central nervous system lymphoma: a retrospective study. J Clin Neurosci 5:409–412. doi:10.1016/S0967-5868(98)90273-9

    Article  PubMed  CAS  Google Scholar 

  2. Shibamoto Y, Tsuchida E, Seki K, Oya N, Hasegawa M, Toda Y, Takemoto M, Sumi M, Hiratsuka J, Oguchi M, Hosono M, Yasuda S, Sougawa M, Kakutoh Y, Hayabuchi N (2004) Primary central nervous system lymphoma in Japan 1995–1999: changes from the preceding 10 years. J Cancer Res Clin Oncol 130:351–356. doi:10.1007/s00432-004-0547-x

    Article  PubMed  Google Scholar 

  3. Quek R, Ty A, Lim ST, See S, Wong MC, Yap SP, Sng I, Hee SW, Tao M (2006) Primary central nervous system lymphoma in an Asian population: a 15-year experience. Onkologie 29:455–459. doi:10.1159/000095342

    Article  PubMed  Google Scholar 

  4. Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J (1996) Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphoma: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 14:556–564

    PubMed  CAS  Google Scholar 

  5. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH (1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43:259–268. doi:10.1023/A:1006210703827

    Article  PubMed  CAS  Google Scholar 

  6. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51–61. doi:10.1097/00006123-200001000-00010

    Article  PubMed  CAS  Google Scholar 

  7. O’Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I, Trotter G (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519–526

    PubMed  CAS  Google Scholar 

  8. Abrey LE, Yahalom J, De Angelis LM (1997) Relapse and late neurotoxicity in primary central nervous system lymphoma. Neurology 48:A18

    Google Scholar 

  9. Siobhan NG, Rosenthal MA, Ashley D, Cher L (2000) High dose methotrexate for primary CNS lymphoma in the elderly. Neuro Oncol 2:40–44. doi:10.1215/15228517-2-1-40

    Article  Google Scholar 

  10. Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J (2001) CHOP/BVAM regimen plus radiotherapy in patients with primary CNS non Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 50:457–464. doi:10.1016/S0360-3016(01)01451-1

    Article  PubMed  CAS  Google Scholar 

  11. Lu X, Nechushtan H, Ding F, Rosado MF, Singal R, Alizadeh AA, Lossos IS (2005) Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood 105:2924–2932. doi:10.1182/blood-2004-10-3820

    Article  PubMed  CAS  Google Scholar 

  12. Bruns HA, Kaplan MH (2006) The role of constitutively active Stat6 in leukemia and lymphoma. Crit Rev Oncol Hematol 57:245–253. doi:10.1016/j.critrevonc.2005.08.005

    Article  PubMed  Google Scholar 

  13. Carey GB, Semenova E, Qi X, Keegan AD (2007) IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contributing of the PI-3 kinase/AKT pathway. Cell Res 17:942–955. doi:10.1038/sj.cr.2007.90

    Article  PubMed  CAS  Google Scholar 

  14. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial glioma. J Clin Oncol 8:1277–1280

    PubMed  CAS  Google Scholar 

  15. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214. doi:10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6

    Article  PubMed  CAS  Google Scholar 

  16. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, Mak TW (2002) Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 15:618–626. doi:10.1182/blood.V99.2.618

    Article  Google Scholar 

  17. Gatter KC, Warnke RA (2002) Diffuse large cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JV (eds) Pathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC, Lyon, pp 171–174

    Google Scholar 

  18. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R, Dana B (1991) Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9:1580–1590

    PubMed  CAS  Google Scholar 

  19. Cher L, Glass J, Harsh GR, Hochberg FH (1996) Therapy of primary central nervous system lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 46:1757–1759

    PubMed  CAS  Google Scholar 

  20. Freilich RJ, Delattre JY, Monjour A, De Angelis LM (1996) Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46:435–439

    PubMed  CAS  Google Scholar 

  21. Hoang-Xuan K, Chinot O, Frenay M, Taillandier L, Hildebrand J, Monjour A, van den Bent M, Sahmoud T, Poisson M, Delattre JY (1997) Chemotherapy alone as initial treatment of primary central nervous system. Neurology 48:A17

    Article  Google Scholar 

  22. Sherman W, Balmaceda C, Nichols G, Mears G, Antman K (1997) Feasibility of 3 g/m2 of intravenous methotrexate for primary central nervous system lymphoma. Neurology 48:A17–A18

    Article  Google Scholar 

  23. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinquely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell’Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphoma: the International Extranodal Lymphoma Study Group Experience. J Clin Oncol 21:266–272. doi:10.1200/JCO.2003.09.139

    Article  PubMed  Google Scholar 

  24. Helle TL, Britt RH, Golby TV (1984) Primary lymphoma of the central nervous system: clinicopathological study of experience at Stanford. J Neurosurg 60:94–103

    Article  PubMed  CAS  Google Scholar 

  25. Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL (1989) Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63:939–947. doi:10.1002/1097-0142(19890301)63:5<939::AID-CNCR2820630526>3.0.CO;2-V

    Article  PubMed  CAS  Google Scholar 

  26. Michalski JM, Garcia DM, Kase E, Griqsby PW, Simpson JR (1990) Primary central nervous system lymphoma: analysis of prognostic variables and patterns of treatment failure. Radiology 176:855–860

    PubMed  CAS  Google Scholar 

  27. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M (2006) Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716–3723. doi:10.1182/blood-2005-03-0897

    Article  PubMed  CAS  Google Scholar 

  28. Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945–954

    PubMed  CAS  Google Scholar 

  29. Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ (2005) Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 11:6333–6341. doi:10.1158/1078-0432.CCR-05-0148

  30. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW (2002) The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 70:537–546. doi:10.1046/j.1432-0436.2002.700907.x

    Article  PubMed  Google Scholar 

  31. Das S, Roth CP, Wasson LM, Vishwanatha JK (2007) Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 67:1550–1564. doi:10.1002/pros.20640

    Article  PubMed  CAS  Google Scholar 

  32. Batchelor T, Carson K, O’Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21:1044–1049. doi:10.1200/JCO.2003.03.036

    Article  PubMed  CAS  Google Scholar 

  33. Herrlinger U, Kuker W, Uhl M, Blaicher H, Karnath H, Kanz L, Bamberg M, Weller M (2005) NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57:843–847. doi:10.1002/ana.20495

    Article  PubMed  CAS  Google Scholar 

  34. Harder H, Holtel H, Bromberg JE (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62:544–547

    PubMed  CAS  Google Scholar 

  35. Chon B, Hochberg F, Loeffler J, Batchelor T (2001) Methotrexate reinduction in patients with relapsed primary central nervous system lymphoma. Neuro Oncol 3:356

    Google Scholar 

  36. Reni M, Mason W, Zaja F, Franceschi E, Bernardi D, Dell’Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJ (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40:1682–1688. doi:10.1016/j.ejca.2004.03.008

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The authors would like to thank Professor Tali Siegal for reviewing the manuscript.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea

    Seung-Ho Yang, Il Sup Kim, Jae Taek Hong, Jae Hoon Sung, Byung Chul Son & Sang Won Lee

  2. Department of Neurosurgery, Kangnam St. Mary’s Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul, 137-701, South Korea

    Kun Soo Lee & Yong-Kil Hong

Authors
  1. Seung-Ho Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kun Soo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Il Sup Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jae Taek Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jae Hoon Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Byung Chul Son
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sang Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yong-Kil Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong-Kil Hong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, SH., Lee, K.S., Kim, I.S. et al. Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant. J Neurooncol 92, 65–71 (2009). https://doi.org/10.1007/s11060-008-9736-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-008-9736-9

Keywords

Search

Navigation